Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older

PHASE3CompletedINTERVENTIONAL
Enrollment

2,680

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Influenza
Interventions
BIOLOGICAL

QIVc

Novartis Investigational Quadrivalent Vaccine

BIOLOGICAL

TIV1c

Licensed Influenza Vaccine

BIOLOGICAL

TIV2c

Novartis Investigational Vaccine

Trial Locations (40)

13760

Endwell

14609

Rochester

20850

Rockville

27518

Cary

27609

Raleigh

28209

Charlotte

28401

Wilmington

29464

Mt. Pleasant

29621

Anderson

32935

Melbourne

33024

Hollywood

33134

Coral Gables

33143

South Miami

33409

West Palm Beach

35802

Huntsville

46545

Mishawaka

51503

Council Bluffs

55435

Edina

57049

Dakota Dunes

61602

Peoria

67114

Newton

67205

Wichita

67207

Wichita

68005

Bellevue

68134

Omaha

70006

Metairie

73112

Oklahoma City

75231

Dallas

76135

Fort Worth

76904

San Angelo

78705

Austin

78745

Austin

84095

South Jordan

84109

Salt Lake City

84121

Salt Lake City

84124

Salt Lake City

85050

Phoenix

92108

San Diego

92801

Anaheim

02886

Warwick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY